DUBLIN, October 30, 2017 /PRNewswire/ --

The "Global Sepsis Diagnostics Market 2017-2021" report has been added to Research and Markets' offering.

The global sepsis diagnostics market to grow at a CAGR of 6.74% during the period 2017-2021.

Global Sepsis Diagnostics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is Increasing use of biomarkers for sepsis. The increased preference for biomarkers offers homogeneity of risk or disease status of the patient within limited time and provides precision diagnosis will increase its adoption rate. Biomarkers are used as diagnostic tools for the diagnosis of a disease or abnormal conditions of sepsis, including severe sepsis. The accuracy and timely detection of sepsis are regarded as the significant challenges. Therefore, the health providers rely on nonspecific clinical and laboratory signs.

According to the report, one of the major drivers for this market is Rising prevalence of hospital acquired infection (HAIs) globally. Increasing cases of HAIs in the population is the leading cause of sepsis. HAI is also known as the nosocomial infection, which may affect the population during hospitalization or after the patient is discharged from the hospital. The presence of immunocompromised patients in hospitals, transmission of the pathogen between the staff and the patient, and the presence of microorganisms and contaminated particles in the hospital environment are the major factors that result in HAIs. The number of cases for HAIs is on the rise across the world, leading to septicemia. This drives the demand for sepsis diagnostics worldwide.

Further, the report states that one of the major factors hindering the growth of this market is High cost of sepsis treatment. The high cost of sepsis treatment is regarded as one of the market constraints, which affects the growth of the sepsis diagnostics market. Therefore, the high price of procedures decreases the adoption rate of this product, especially in the reference laboratories and small clinics where the budget allocated is very less. However, the cost-efficient treatment is likely to increase the adoption rate during the forecast period.

Key Market trends

• Development of novel products
• Increasing use of biomarkers for sepsis
• Increasing online campaigns for sepsis awareness

Key vendors

• bioMrieux
• T2 Biosystems

Other prominent vendors

• Alere
• Abionic
• AdvanDx
• Aethlon Medical
• AusDiagnostics
• Beckman Coulter
• Beckton Dickinson
• Momentum Bioscience
• Bio-Rad Laboratories
• Bruker
• Cepheid
• Curetis
• CytoSorbents
• Fast Track Diagnostics
• F. Hoffmann-La Roche
• Fujirebio Europe
• Hansa Medical
• Hain Lifescience
• Immunexpress
• Inflammatix
• Merck
• miacom diagnostics
• Mitsubishi Chemical Europe
• Nanomix
• QIAGEN
• Radiometer
• Response Biomedical
• Sepset Biosciences
• Siemens Healthineers
• TCS Biosciences
• Thermo Fisher Scientific
  

Key Topics Covered:

1. Executive Summary
2. Scope Of The Report
3. Research Methodology
4. Introduction
5. Market Landscape
6. Market Segmentation By Technology
7. Market Segmentation By End-User
8. Geographical Segmentation
9. Decision Framework
10. Drivers And Challenges
11. Market Trends
12. Vendor Landscape
13. Key Vendors
14. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/6bmwhz/global_sepsis

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets